EMS-CHEMIE HOLDING AG : The underlying trend is in force again
Entry price | Target | Stop-loss | Potential |
---|
CHF 912.5 |
CHF 990 |
CHF 841 |
+8.49% |
---|
EMS-CHEMIE HOLDING AG's shares display attractive technical aspects to anticipate a comeback of the underlying trend.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths●
● The group's activity appears highly profitable thanks to its outperforming net margins.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Sales forecast by analysts have been recently revised upwards.
●
●
●
● Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
● Historically, the company has been releasing figures that are above expectations.
Weaknesses● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.79 times its estimated earnings per share for the ongoing year.
● Based on current prices, the company has particularly high valuation levels.
●
●
● The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
●
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.